Innovation Award from Pharma Partner

Oxford Pharmascience Group plc ("Oxford Pharmascience" or "the Company")

Oxford Pharmascience receives Innovation Award from pharma partner

Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces that it was awarded the Innovation Award 2013 by Aché Laboratórios, its pharma partner in Brazil.

The award recognises the success of Aché's Inellare brand launched with technology and supply chain support provided by Oxford Pharmascience. The product was launched in early 2012 and it is growing strongly with both companies working in close partnership to support a growing pipeline of products under the brand. Aché is one of the largest local pharmaceutical companies with a strong presence in the Brazilian market which is one of the largest and most dynamic pharmaceutical markets in the emerging economies, reaching US$22.9 billion in 2010.

Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience commented, "We are delighted to be recognised as the most innovative supplier by our partner Aché, one of the largest emerging markets pharmaceutical companies. This demonstrates our business model of developing and licensing innovative best-in- class products to major pharmaceutical companies and validates our ability to deliver. We look forward to continuing to work with Aché Laboratorios to deliver innovation in Brazil and the rest of South America".

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

N+1 Singer

Shaun Dobson/Jenny Wyllie +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.